305
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study

, , , , , & show all
Pages 9-21 | Received 19 May 2022, Accepted 10 Dec 2022, Published online: 04 Jan 2023

References

  • Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. A pocket guide for health professionals; 2021. Available from: https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention. Accessed November 2, 2022.
  • Rönnebjerg L, Axelsson M, Kankaanranta H, et al. Severe asthma in a general population study: prevalence and clinical characteristics. J Asthma Allergy. 2021;14:1105–1115. doi:10.2147/JAA.S327659
  • Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
  • Global Initiative for Asthma (GINA). Diagnosis and management of difficult-to-treat and severe asthma. Difficult-to-treat & severe asthma in adolescent and adult patients. A GINA Pocket Guide for health professionals. V3.0; 2021. Available from: https://ginasthma.org/severeasthma. Accessed November 2, 2022.
  • Bourdin A, Fabry-Vendrand C, Ostinelli J, et al. The burden of severe asthma in France: a case-control study using a medical claims database. J Allergy Clin Immunol Pract. 2019;7(5):1477–1487. doi:10.1016/j.jaip.2018.12.029
  • Gruffydd-Jones K. Unmet needs in asthma. Ther Clin Risk Manag. 2019;15:409–421. doi:10.2147/TCRM.S160327
  • Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506
  • Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. doi:10.1164/rccm.201611-2232PP
  • Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267–281. doi:10.2147/JAA.S153097
  • Haute Autorité de Santé (HAS). Asthmes sévères: quels traitements proposer et dans quels cas? Communiqué de presse [Severe asthma: which treatments to offer and in which cases?]; 2018. French. French: https://www.has-sante.fr/jcms/c_2823952/fr/asthmes-severes-quels-traitements-proposer-et-dans-quels-cas. Accessed November 2, 2022.
  • Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis. 2016;10(3):211‑234. doi:10.1177/1753465816632638
  • Abe Y, Suga Y, Fukushima K, et al. Advances and challenges of antibody therapeutics for severe bronchial asthma. Int J Mol Sci. 2021;23(1):83. doi:10.3390/ijms23010083
  • Portel L, Parrat E, Nocent-Ejnaini C, et al. FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals. ERJ Open Res. 2019;5(4):00069–2019. doi:10.1183/23120541.00069-2019
  • Coëtmeur D, Parrat E, Nocent-Ejnaini C, et al. Activité physique et asthme sévère: résultats de l’étude FASE-CPHG [Physical activity in severe asthma: results of the FASE-CPHG Study]. Rev Mal Respir. 2020;37(4):320–327. French. doi:10.1016/j.rmr.2019.12.004
  • Raherison-Semjen C, Parrat E, Nocent-Eijnani C, et al. CPHG (College of French Non-academic Hospitals). FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis. Respir Res. 2021;22(1):136. doi:10.1186/s12931-021-01723-x
  • Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002;57(7):643–648. doi:10.1136/thorax.57.7.643
  • Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814–830. doi:10.1016/j.chest.2021.04.013
  • Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:10.1111/all.13302
  • Yonas MA, Marsland AL, Emeremni CA, Moore CG, Holguin F, Wenzel S. Depressive symptomatology, quality of life and disease control among individuals with well-characterized severe asthma. J Asthma. 2013;50(8):884–890. doi:10.3109/02770903.2013.810750
  • Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology. 2017;22(4):651–661. doi:10.1111/resp.13026
  • Ciprandi G, Schiavetti I, Rindone E, Ricciardolo FLM. The impact of anxiety and depression on outpatients with asthma. Ann Allergy Asthma Immunol. 2015;115(5):408–414. doi:10.1016/j.anai.2015.08.007